Immunic has commenced phase II CALVID-1 clinical trials of their IMU-838 therapy to treat patients with coronavirus. The U.S.-based biotech firm expects trial results later in the year. Yourway has the global capacity to transport sensitive trial materials and deliver trial material directly to patients.